Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study

• Asıl Yazarlar: Hao Liang (Yazar), Zhenling Deng (Yazar), Shu Niu (Yazar), Weijie Kong (Yazar), Yang Liu (Yazar), Song Wang (Yazar), Haiyan Li (Yazar), Yue Wang (Yazar), Danxia Zheng (Yazar), Dongyang Liu (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2024-03-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Primary membranous nephropathy (PMN) is the most common cause for adult nephrotic syndrome. Rituximab has demonstrated promising clinical efficacy by random controlled trials and the off-label use is widely adopted in PMN. However, the standard dosage is borrowed from B cell lymphoma treatment with...